All In Biotech

Drug Trial Radar · NCT02617459

Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension

A Multicenter, Randomized, Open-label, Positive-controlled, Parallel-group Clinical Trial of Levobetaxolol Hydrochloride Eye Drops in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

Last checked: Nov 20, 2026Latest source record: May 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 366 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

366

Actual

Start

Jan 4, 2019

Primary completion

Jul 1, 2021

Study completion Jul 1, 2021

Sponsor

Sponsor type
Industry
First posted
Dec 1, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and efficacy of Levobetaxolol in Chinese patients with glaucoma.

Conditions

  • Primary Open-angle Glaucoma
  • Ocular Hypertension

Interventions

  • Levobetaxolol eye dropsDrug

    one drop per time; twice daily

  • Betaxolol eye dropsDrug

    one drop per time; twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in intraocular pressure (IOP) from baseline at week 8 after the treatment (a.m.)Time frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan ophthalmic center, Sun Yat-sen University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.